GlassScriptPhysician profile
Emily B Williams
NPI 1659593655
$11,485.91
in general payments reported to CMS, 2019-2025
43 companies · $1,235 in 2025
The $1,235 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,127 · 2020: $1,744 · 2021: $1,872 · 2022: $1,747 · 2023: $1,655 · 2024: $2,105 · 2025: $1,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,995.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,550.00 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,542.80 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $1,239.74 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $1,097.22 | 2020-2025 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $1,035.98 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Pfizer INC. | $775.25 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $655.89 | 2019-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $575.23 | 2019-2025 | Trintellix |
| Allergan, INC. | $333.50 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.69 | 2019-2025 | Jardiance, Jascayd |
| Amgen INC. | $290.19 | 2019-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $205.72 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $185.17 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Ironwood Pharmaceuticals, INC | $156.33 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $145.78 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.